Similar articles

• Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder.

  Jenike MA, Baer L, Minichiello WE, Rauch SL, Buttolph ML. Jenike MA, et al. Am J Psychiatry. 1997 Sep;154(9):1261-4. doi: 10.1176/ajp.154.9.1261. Am J Psychiatry. 1997. PMID: 9286186 Clinical Trial.
• Should young people be given antidepressants? No.

  Timimi S. Timimi S. BMJ. 2007 Oct 13;335(7623):751. doi: 10.1136/bmj.39316.406470.94. BMJ. 2007. PMID: 17932206 Free PMC article.
• Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.

  Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L. Mataix-Cols D, et al. Am J Psychiatry. 1999 Sep;156(9):1409-16. doi: 10.1176/ajp.156.9.1409. Am J Psychiatry. 1999. PMID: 10484953
• A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.

  Pigott TA, Seay SM. Pigott TA, et al. J Clin Psychiatry. 1999 Feb;60(2):101-6. doi: 10.4088/jcp.v60n0206. J Clin Psychiatry. 1999. PMID: 10084636 Review.
• Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.

  Flament MF, Bisserbe JC. Flament MF, et al. J Clin Psychiatry. 1997;58 Suppl 12:18-22. J Clin Psychiatry. 1997. PMID: 9393392 Review.